HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Durif, F. Articles by Agid, Y. Search for Related Content PubMed PubMed Citation Articles by Durif, F. Articles by Agid, Y.

Levodopa-induced dyskinesias are improved by fluoxetine

From INSERM U 289, Hopital de la Salpetriere, Paris, France.
Received August 1, 1994. Accepted in final form March 6, 1995.
Address correspondence and reprint requests to Dr. F. Durif, INSERM U 289, Hopital de la Salpetriere, 47, bd de l'Hopital, 75651 Paris Cedex 13, France.

We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 plus minus 1 days. After fluoxetine treatment, there was a significant 47% improvement (p less than 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.

NEUROLOGY 1995;45: 1855-1858

This article has been cited by other articles:

				B. Thanvi, N. Lo, and T. Robinson Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment Postgrad. Med. J., June 1, 2007; 83(980): 384 - 388. [Abstract] [Full Text] [PDF]

				A H V Schapira Present and future drug treatment for Parkinson's disease J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1472 - 1478. [Abstract] [Full Text] [PDF]

				K. A. Chung, N. E. Carlson, and J. G. Nutt Short-term paroxetine treatment does not alter the motor response to levodopa in PD Neurology, May 24, 2005; 64(10): 1797 - 1798. [Abstract] [Full Text] [PDF]

				S. Threlfell, S. J. Cragg, I. Kallo, G. F. Turi, C. W. Coen, and S. A. Greenfield Histamine H3 Receptors Inhibit Serotonin Release in Substantia Nigra Pars Reticulata J. Neurosci., October 6, 2004; 24(40): 8704 - 8710. [Abstract] [Full Text] [PDF]

				M. J. Hansard, L. A. Smith, M. J. Jackson, S. C. Cheetham, and P. Jenner Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 952 - 958. [Abstract] [Full Text] [PDF]

				J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]

				A. J. Manson, A. Schrag, and A. J. Lees Low-dose olanzapine for levodopa induced dyskinesias Neurology, September 26, 2000; 55(6): 795 - 799. [Abstract] [Full Text] [PDF]

				A. E. Lang and A. M. Lozano Parkinson's Disease- Second of Two Parts N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143. [Full Text] [PDF]

				Some Reminders That Serotonin Also Affects Neurologic Conditions Journal Watch Psychiatry, December 1, 1995; 1995(1201): 11 - 11. [Full Text]